These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 22792354)

  • 1. In vitro assays using primary embryonic mouse lymphatic endothelial cells uncover key roles for FGFR1 signalling in lymphangiogenesis.
    Kazenwadel J; Secker GA; Betterman KL; Harvey NL
    PLoS One; 2012; 7(7):e40497. PubMed ID: 22792354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The β
    Kumaravel S; Abbey CA; Bayless KJ; Chakraborty S
    Am J Physiol Cell Physiol; 2020 Dec; 319(6):C1045-C1058. PubMed ID: 33052069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of VEGF-induced migration and network formation by lymphatic endothelial cells: Roles of platelets and podoplanin.
    Langan SA; Navarro-Núñez L; Watson SP; Nash GB
    Platelets; 2018 Jul; 29(5):486-495. PubMed ID: 28727496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor-C secreted by pancreatic cancer cell line promotes lymphatic endothelial cell migration in an in vitro model of tumor lymphangiogenesis.
    Ochi N; Matsuo Y; Sawai H; Yasuda A; Takahashi H; Sato M; Funahashi H; Okada Y; Manabe T
    Pancreas; 2007 May; 34(4):444-51. PubMed ID: 17446844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor superfamily member 15 (Tnfsf15) facilitates lymphangiogenesis via up-regulation of Vegfr3 gene expression in lymphatic endothelial cells.
    Qin TT; Xu GC; Qi JW; Yang GL; Zhang K; Liu HL; Xu LX; Xiang R; Xiao G; Cao H; Wei Y; Zhang QZ; Li LY
    J Pathol; 2015 Nov; 237(3):307-18. PubMed ID: 26096340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGFβ counteracts LYVE-1-mediated induction of lymphangiogenesis by small hyaluronan oligosaccharides.
    Bauer J; Rothley M; Schmaus A; Quagliata L; Ehret M; Biskup M; Orian-Rousseau V; Jackson DG; Pettis RJ; Harvey A; Bräse S; Thiele W; Sleeman JP
    J Mol Med (Berl); 2018 Feb; 96(2):199-209. PubMed ID: 29282520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total saponins of panaxnotoginseng promotes lymphangiogenesis by activation VEGF-C expression of lymphatic endothelial cells.
    Li J; Chen Y; Zhang L; Xing L; Xu H; Wang Y; Shi Q; Liang Q
    J Ethnopharmacol; 2016 Dec; 193():293-302. PubMed ID: 27553977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer.
    Lala PK; Nandi P; Majumder M
    Cancer Metastasis Rev; 2018 Sep; 37(2-3):369-384. PubMed ID: 29858743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equine Endothelial Cells Show Pro-Angiogenic Behaviours in Response to Fibroblast Growth Factor 2 but Not Vascular Endothelial Growth Factor A.
    Finding EJT; Faulkner A; Nash L; Wheeler-Jones CPD
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGFβ signaling is required for sprouting lymphangiogenesis during lymphatic network development in the skin.
    James JM; Nalbandian A; Mukouyama YS
    Development; 2013 Sep; 140(18):3903-14. PubMed ID: 23946447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel application assigned to toluquinol: inhibition of lymphangiogenesis by interfering with VEGF-C/VEGFR-3 signalling pathway.
    García-Caballero M; Blacher S; Paupert J; Quesada AR; Medina MA; Noël A
    Br J Pharmacol; 2016 Jun; 173(12):1966-87. PubMed ID: 27018653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.
    Shin JW; Huggenberger R; Detmar M
    Blood; 2008 Sep; 112(6):2318-26. PubMed ID: 18614759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.
    Nandi P; Girish GV; Majumder M; Xin X; Tutunea-Fatan E; Lala PK
    BMC Cancer; 2017 Jan; 17(1):11. PubMed ID: 28056899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow-derived mesenchymal stem cells drive lymphangiogenesis.
    Maertens L; Erpicum C; Detry B; Blacher S; Lenoir B; Carnet O; Péqueux C; Cataldo D; Lecomte J; Paupert J; Noel A
    PLoS One; 2014; 9(9):e106976. PubMed ID: 25222747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
    García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
    J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphangiogenic growth factors, receptors and therapies.
    Lohela M; Saaristo A; Veikkola T; Alitalo K
    Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34+ VEGFR-3+ progenitor cells have a potential to differentiate towards lymphatic endothelial cells.
    Tan YZ; Wang HJ; Zhang MH; Quan Z; Li T; He QZ
    J Cell Mol Med; 2014 Mar; 18(3):422-33. PubMed ID: 24450475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
    Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
    BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.